Mack F, Baumert BG, Schäfer N, Hattingen E, Scheffler B, Herrlinger U, Glas M (2016) Therapy of leptomeningeal metastasis in solid tumors. Cancer Treat Rev 43:83–91

Article  PubMed  CAS  Google Scholar 

Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ (2017) Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol 19(1):i1–i24

Article  PubMed  CAS  Google Scholar 

Smalley KS, Fedorenko IV, Kenchappa RS, Sahebjam S, Forsyth PA (2016) Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. Int J Cancer 139(6):1195–1201

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wen L, Cai L (2023) Primary diffuse Meningeal Melanomatosis. N Engl J Med 388(20):1892

Article  PubMed  Google Scholar 

Piña Y, Yadugiri S, Yeboa DN, Ferguson SD, Forsyth PA, Oliva ICG (2022) Advances in diagnosis and treatment for Leptomeningeal Disease in Melanoma. Curr Oncol Rep 24(1):43–54

Article  PubMed  Google Scholar 

Long GV, Atkinson V, Lo S, Guminski AD, Sandhu SK, Brown MP, Gonzalez M, Scolyer RA, Emmett L, McArthur GA, Menzies AM (2021) Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): randomized phase 2 study of nivolumab (nivo) or nivo + ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). J Clin Oncol 2021 39:15_suppl, 9508–9508

Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV (2017) Dabrafenib plus Trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863–873

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, Thomas RP, Glaspy J, Jang S, Khushalani NI, Pavlick AC, Ernstoff MS, Reardon DA, Kudchadkar R, Tarhini A, Chung C, Ritchings C, Durani P, Askelson M, Puzanov I, Margolin KA (2021) Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol 22(12):1692–1704

Article  PubMed  PubMed Central  CAS  Google Scholar 

Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687–1696

Article  PubMed  Google Scholar 

Sampson JH, Carter JH Jr, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88(1):11–20

Article  PubMed  CAS  Google Scholar 

Fan C, Zhao Q, Li L, Shen W, Du Y, Teng C, Gao F, Song X, Jiang Q, Huang D, Jin Y, Lv Y, Wei L, Shi T, Zhao X, Gao N, Jiang Z, Xin T (2021) Efficacy and Safety of Intrathecal Pemetrexed Combined with Dexamethasone for treating tyrosine kinase inhibitor-failed Leptomeningeal metastases from EGFR-Mutant NSCLC-a prospective, Open-Label, single-arm phase 1/2 clinical trial (unique identifier: ChiCTR1800016615). J Thorac Oncol 16(8):1359–1368

Article  PubMed  CAS  Google Scholar 

Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL Jr, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA (2018) Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3(1):e000283

Article  PubMed  PubMed Central  Google Scholar 

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A (2019) Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 30(4):582–588

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C (2017) Pembrolizumab versus Ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390(10105):1853–1862

Article  PubMed  CAS  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD (2019) Five-year survival with combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 381(16):1535–1546

Article  PubMed  CAS  Google Scholar 

Glitza Oliva IC, Ferguson SD, Bassett R Jr, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O’Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Burton EM, Tawbi HA, Davies MA (2023) Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med 29(4):898–905

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J (2011) Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11:85

Article  PubMed  PubMed Central  Google Scholar 

Chi Z, Tang B, Sheng X, Si L, Cui C, Kong Y, Chen Y, Qin S, Chen J, Wu D, Song X (2018) A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China. J Clin Oncol 2018(suppl; abstr 9539).

Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rudà R, Preusser M (2017) EANO Executive Board and ESMO Guidelines Committee. EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol 28(suppl4):iv84–iv99

Article  PubMed  Google Scholar 

Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Walker J, van den Bent M, Wen PY, Jaeckle KA (2017) Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol 19(4):484–492

PubMed  Google Scholar 

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schadendorf D, Hodi FS, Robert C et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889–1894

Article  PubMed  PubMed Central  CAS  Google Scholar 

Margolin K, Ernstoff MS, Hamid O et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459–465

Article  PubMed  CAS  Google Scholar 

Bot I, Blank CU, Brandsma D (2012) Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol 259(9):1976–1978

Article  PubMed  CAS  Google Scholar 

Wu RC, Newman W, Patanowitz L, Branstetter BF, Amankulor N, Tarhini AA (2020) Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient. Immunotherapy 12(11):763–769

Article  PubMed  PubMed Central  CAS  Google Scholar 

Glitza I, Bucheit A (2017) Clinical response of central nervous system melanoma to anti-PD1 therapy in 2 melanoma patients. Arch Immunol 1(1):1–3

Google Scholar 

Samlowski WE, Park KJ, Galinsky RE, Ward JH, Schumann GB (1993) Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J Immunother Emphas Tumor Immunol 13(1):49–54

Article  CAS  Google Scholar 

Ferguson SD, Bindal S, Bassett RL Jr., Haydu LE, McCutcheon IE, Heimberger AB, Li J, O’Brien BJ, Guha-Thakurta N, Tetzlaff MT et al (2019) Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol 142:499–509

Article  PubMed  CAS  Google Scholar 

Chorti E, Kebir S, Ahmed MS, Keyvani K, Umutlu L, Kanaki T, Zaremba A, Reinboldt-Jockenhoefer F, Knispel S, Gratsias E et al (2021) Leptomeningeal disease from melanoma—poor prognosis despite new therapeutic modalities. Eur J Cancer 148:395–404

Article  PubMed  CAS  Google Scholar